BOSTON, June 16, 2006 — VLST Corp., a Seattle-based developer of therapeutics for autoimmune and inflammatory disorders, has raised $55 million in Series B funding. The financing was led by Texas Pacific Group Ventures and included participation from existing investors MPM Capital, ARCH Venture Partners, and OVP Venture Partners. New investors MedImmune Ventures Inc. and WRF Capital, venture investment arm of the Washington Research Foundation, also participated in the financing. The VLST platform uses bioinformatics and proteomics to identify viral genes whose protein products function as immunomodulatory agents.
Press Release June 16, 2006